Titre du document / Document title

Hip status in cerebral palsy after one year of continuous intrathecal baclofen infusion

Auteur(s) / Author(s)

KRACH Linda E. ⁽¹⁾ ; KRIEL Robert L. ⁽²⁾ ; GILMARTIN Richard C. ⁽³⁾ ; SWIFT Dale M. ⁽⁴⁾ ; STORRS Bruce B. ⁽⁵⁾ ; ABBOTT Rick ⁽⁶⁾ ; WARD John D. ⁽⁷⁾ ; BLOOM Karen K. ⁽⁸⁾ ; BROOKS William H. ⁽⁹⁾ ; MADSEN Joseph R. ⁽¹⁰⁾ ; MCLAUGHLIN John F. ⁽¹¹⁾ ; NADELL Joseph M. ⁽¹²⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Pediatric Rehabilitation Medicine at Gillette Children's Specialty Healthcare, St. Paul, Minnesota, ETATS-UNIS
⁽²⁾ Pediatrics and Neurology at Hennepin County Medical Center, Minneapolis, Minnesota, ETATS-UNIS
⁽³⁾ Department of Pediatrics, University of Kansas School of Medicine, Kansas City, Kansas, ETATS-UNIS
⁽⁴⁾ Department of Neurosurgery, Children's Medical Center of Dallas, Dallas, Texas, ETATS-UNIS
⁽⁵⁾ Division of Neurosurgery, Children's Hospital of New Mexico, Albequerque, New Mexico, ETATS-UNIS
⁽⁶⁾ Division of Pediatric Neurosurgery, Beth Israel Medical Center, Singer Division, New York, New York, ETATS-UNIS
⁽⁷⁾ Division of Neurosurgery Medical College of Virginia, Richmond, Virginia, ETATS-UNIS
⁽⁸⁾ Division of Physical Medicine and Rehabilitation, Frazier Rehabilitation Center, Louisville, Kentucky, ETATS-UNIS
⁽⁹⁾ Department of Neurosurgery, Pain Care Center, Lexington, Kentucky, ETATS-UNIS
⁽¹⁰⁾ Department of Neurosurgery, Children's Hospital of Boston, Boston, Massachusetts, ETATS-UNIS
⁽¹¹⁾ Department of Pediatrics, Children's Hospital and Medical Center, Seattle, Washington, ETATS-UNIS
⁽¹²⁾ Division of Neuroscience, Children's Hospital of Louisiana, New Orleans, Louisiana, ETATS-UNIS

Résumé / Abstract

The purpose of this study was to assess whether reduction of muscle tone by continuous intrathecal baclofen infusion affects the progression of hip subluxation in persons with cerebral palsy. This prospective, open-label, case series was conducted at multiple specialty referral centers. There were 33 subjects, ages 4 to 31 years. All had a pretreatment lower extremity Ashworth score of ≥3; all subjects had a significant reduction in tone after a bolus injection of intrathecal baclofen and received an implanted pump for continuous delivery of intrathecal baclofen. Subjects had hip x-rays before and 1 year after pump implantation. The primary outcome measure was change in absolute hip migration percentage. One third of the hips had an increase of absolute migration percentage of 5% or more; 12% of the hips had a decrease of migration percentage of 5% or more. Change of migration percentage class was used as a second outcome criterion. 90.9% of hips manifested no deterioration or had improvement of their migration percentage class during the year of intrathecal baclofen therapy. The observed changes were not associated with the subject's age or the severity of cerebral palsy.

Revue / Journal Title

Pediatric neurology   ISSN 0887-8994 

Source / Source

Congrès
Annual Meeting of the American Academy of Physical Medicine and Rehabilitation, San Francisco, CA , ETATS-UNIS (04/11/2000)
2004, vol. 30, n^o3, pp. 163-168 [6 page(s) (article)] (10 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier, New York, NY, ETATS-UNIS  (1985) (Revue)

Mots-clés anglais / English Keywords

Central nervous system disease ; Cerebral disorder ; Gabaergic agonist ; Gabaergic receptor B ; Agonist ; Baclofen ; Nervous system diseases ; Intrathecal ; Hip ; Cerebral palsy ;

Mots-clés français / French Keywords

Système nerveux central pathologie ; Encéphale pathologie ; Stimulant gabaergique ; Récepteur gabaergique B ; Agoniste ; Baclofène ; Système nerveux pathologie ; Intrarachidien ; Hanche ; Infirmité motrice cérébrale ;

Mots-clés espagnols / Spanish Keywords

Sistema nervosio central patología ; Encéfalo patología ; Estimulante gabaérgico ; Receptor gabaminérgico B ; Agonista ; Baclofeno ; Sistema nervioso patología ; Intratecal ; Cadera ; Encefalopatía infantil ;

Localisation / Location

INIST-CNRS, Cote INIST : 22170, 35400011148898.0020